Clinical Trials Logo

Clinical Trial Summary

The purpose of this extension study is to continue to follow the participants who completed the CLVer RCT for up to 3 additional years. The goal for Cohort A is to evaluate the longer-term effects of verapamil on preservation of β-cell function as measured by C-peptide levels obtained during a mixed meal tolerance test (MMTT). For both Cohorts A and B, the goal is to determine if the high degree of glycemic control achieved during CLVer with HCL can be maintained once the intensive engagement of the study team is discontinued. At the completion of the RCT, study treatments end. Thus, during the extension study, diabetes management is performed as part of usual care and there is no study treatment.


Clinical Trial Description

Participants who complete the CLVer RCT will be eligible to enroll in the CLVer Extension Study. Informed consent and assent, when applicable, will be obtained. Participants will be contacted every 3 months at which time continuous glucose monitoring (CGM) data will be obtained if a CGM device is being used and medical history (including recent point-of-care or local laboratory HbA1c values) will be reviewed; a usual care visit performed by study staff may be considered a study contact. A study visit will occur yearly to update the diabetes and medical history, measure height and weight, determine Tanner staging, download CGM data if available, perform an MMTT, and obtain blood samples for central lab measurement of HbA1c and plasma for storage if consented. Other than the central lab samples, there are no study-specific procedures or data collection that would not be performed as part of standard care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06177691
Study type Observational
Source Jaeb Center for Health Research
Contact
Status Active, not recruiting
Phase
Start date May 7, 2021
Completion date December 18, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05536232 - Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet N/A
Completed NCT04255381 - Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID) N/A
Completed NCT04625595 - Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes Phase 1
Completed NCT04002557 - Optimising Consultation Summaries to Promote Good Health
Completed NCT05876273 - Neural-net Artificial Pancreas (NAP) N/A
Withdrawn NCT03236558 - The Role of the Thymus in Type I Diabetes. N/A
Completed NCT03179280 - Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia N/A
Completed NCT06253351 - Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes
Completed NCT01357603 - Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM Phase 1
Completed NCT04233034 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes Phase 3
Not yet recruiting NCT06408207 - CGM Academy for Youth With Type 1 Diabetes N/A
Recruiting NCT06408558 - Safe Use of New Technologies in Diabetes in Flight N/A
Active, not recruiting NCT03782636 - Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) Phase 2
Completed NCT04520971 - Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes N/A
Recruiting NCT05766657 - Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases N/A
Completed NCT01838083 - Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus Phase 1